Exact Sciences Corp (EXAS) has disclosed a new risk, in the Regulation category.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Exact Sciences Corp faces significant risks due to potential disruptions at the FDA and other regulatory bodies, which could arise from government shutdowns, policy shifts, or funding issues. These disruptions may lead to delays or denials in the approval of new products, adversely affecting the company’s business and financial health. The unpredictability of government funding and political processes further exacerbates these risks, as seen in past and potential future shutdowns. Such events could materially impact the company’s operations by hindering timely regulatory reviews and approvals.
Overall, Wall Street has a Strong Buy consensus rating on EXAS stock based on 18 Buys and 2 Holds.
To learn more about Exact Sciences Corp’s risk factors, click here.